MARKET

PBLA

PBLA

Panbela Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.000
-0.020
-1.96%
Opening 09:54 08/18 EDT
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.020
LOW
1.000
VOLUME
1.21K
TURNOVER
611
52 WEEK HIGH
2.540
52 WEEK LOW
0.5909
MARKET CAP
20.77M
P/E (TTM)
-1.1999
1D
5D
1M
3M
1Y
5Y
Panbela Therapeutics GAAP EPS of -$1.51
Panbela Therapeutics press release (<span class="ticker-hover-wrapp...
Seekingalpha · 2d ago
BRIEF-Panbela Reports Q2 2022 Financial Results
BRIEF-Panbela Reports Q2 2022 Financial Results
Reuters · 2d ago
Earnings Scheduled For August 15, 2022
  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Benzinga · 3d ago
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Expects interim data by early 2024MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today ann...
GlobeNewswire · 08/11 13:00
Panbela Therapeutics Says it Has Australian Clearance to Expand Trial of SBP-101 to Treat Pancreatic Cancer
Panbela Therapeutics Says it Has Australian Clearance to Expand Trial of SBP-101 to Treat Pancreatic Cancer
MT Newswires · 08/04 13:44
Panbela Expands Aspire Trial To Australia, Studying SBP-101 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has received approval from the
Benzinga · 08/04 13:07
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has received approval fr...
GlobeNewswire · 08/04 13:00
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results
MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a confere...
GlobeNewswire · 08/01 20:00
More
No Data
Learn about the latest financial forecast of PBLA. Analyze the recent business situations of Panbela Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PBLA stock price target is 8.00 with a high estimate of 13.00 and a low estimate of 5.00.
High13.00
Average8.00
Low5.00
Current 1.000
EPS
Actual
Estimate
-1.21-0.91-0.60-0.30
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 16
Institutional Holdings: 845.34K
% Owned: 4.07%
Shares Outstanding: 20.77M
TypeInstitutionsShares
Increased
1
17.58K
New
1
13.96K
Decreased
5
37.86K
Sold Out
2
136.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.71%
Pharmaceuticals & Medical Research
-0.65%
Key Executives
Chairman/Director
Michael Cullen
President/Chief Executive Officer/Director
Jennifer Simpson
Non-Executive Vice Chairman/Lead Director/Independent Director
Jeffrey Mathiesen
Chief Financial Officer/Vice President - Finance/Treasurer/Secretary
Susan Horvath
Director
Suzanne Gagnon
Independent Director
Arthur Fratamico
Independent Director
Paul Schaffer
Independent Director
Donald Schemel
No Data
No Data
About PBLA
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The Company is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.

Webull offers kinds of Panbela Therapeutics Inc stock information, including NASDAQ:PBLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PBLA stock methods without spending real money on the virtual paper trading platform.